LipoScience Names Timothy J. Fischer Chief Operating Officer

RALEIGH, N.C.--(BUSINESS WIRE)--

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical tests using nuclear magnetic resonance (NMR) technology, today announced that Timothy J. Fischer has been named Chief Operating Officer. Mr. Fischer joined LipoScience in 2010 as Vice President of Research and Development. In his new role, Mr. Fischer will oversee research and development, commercial operations and medical affairs.

“In a very short time, Tim has helped shape our corporate strategy and our culture. He has enhanced our ability to effectively achieve our goals with the collective effort of cross-functional teams,” said Richard O. Brajer, Chief Executive Officer of LipoScience. “His leadership will be essential in achieving our core strategies of market conversion, platform expansion and changing the clinical standard of care.”

With more than 25 years of experience, Mr. Fischer is a recognized leader in the in vitro diagnostics industry. He has extensive familiarity in the design, development and commercialization of over 90 products in the fields of hematology, oncology and pathology. Prior to joining LipoScience, Mr. Fischer most recently served as Vice President of Development for the women's health and cancer business at Becton Dickinson. During his career, he has been granted more than 35 patents, has authored numerous publications and has successfully brought several novel technologies and assays to the clinical market. Mr. Fischer has a Bachelor of Science degree in Biology from Indiana University.

Mr. Fischer added, “Our flagship product, the NMR LipoProfile^® test, will potentially drive a paradigm shift in cardiovascular management and treatment and our technology platform may pave the way for a new generation of fully automated clinical metabolomic assays. I am excited to help lead this important effort.”

About LipoScience, Inc.

LipoScience, Inc. is an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary technology platform based on nuclear magnetic resonance (NMR) technology. Our first diagnostic test, the NMR LipoProfile^® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 6.5 million NMR LipoProfile tests have been ordered by clinicians. For further information on the Company, please visit www.liposcience.com and www.theparticletest.com.